Cibus (NASDAQ:CBUS – Get Free Report) and MannKind (NASDAQ:MNKD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.
Risk and Volatility
Cibus has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Cibus and MannKind, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cibus | 1 | 1 | 1 | 0 | 2.00 |
| MannKind | 1 | 2 | 7 | 0 | 2.60 |
Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 643.80%. MannKind has a consensus price target of $8.50, suggesting a potential upside of 121.07%. Given Cibus’ higher probable upside, equities research analysts plainly believe Cibus is more favorable than MannKind.
Valuation and Earnings
This table compares Cibus and MannKind”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cibus | $3.64 million | 25.48 | -$127.08 million | ($1.50) | -0.81 |
| MannKind | $348.97 million | 3.54 | $5.86 million | ($0.23) | -16.72 |
MannKind has higher revenue and earnings than Cibus. MannKind is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
33.8% of Cibus shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 29.9% of Cibus shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Cibus and MannKind’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cibus | -2,131.38% | -526.66% | -28.12% |
| MannKind | -18.10% | N/A | -10.01% |
Summary
MannKind beats Cibus on 9 of the 14 factors compared between the two stocks.
About Cibus
Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
